Domain Therapeutics SA-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Domain Therapeutics SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013198
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Domain Therapeutics SA (Domain Therapeutics) is a biopharmaceutical company that discovers and develops innovative therapeutics for the treatment of Central Nervous System (CNS) diseases and cancer by using transmembrane and G Protein-Coupled Receptor (GPCR) platform.
Its pipeline consists of investigational candidates targeted at the treatment of Parkinson’s disease; cancer, and pain. Domain Therapeutics employs its proprietary drug delivery platform namely DTect-All and BioSens-All. Futher, it conducts research on drug discovery technologies. The company works in partnership with Clevexel Pharma, Prexton Therapeutics and Ono Pharma. It has operations in France and Canada. Domain Therapeutics is headquartered in Illkirch-Strasbourg, France.

Domain Therapeutics SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Domain Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Domain Therapeutics SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Domain Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Domain Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Domain Therapeutics SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Domain Therapeutics SA, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Mavalon Therapeutics to Raise USD10 Million in Venture Financing 10
Domain Therapeutics Raises US$2.5 Million In Venture Financing 11
Partnerships 12
Domain Therapeutics Enters into Partnership with Pfizer 12
Domain Therapeutics Enters into Agreement with Xoma 13
Ono Pharma Enters Into Drug Discovery Agreement With Domain Therapeutics 14
Licensing Agreements 15
Merck Enters into Licensing Agreement with Domain Therapeutics 15
Alkermes Enters into Licensing Agreement with Domain Therapeutics 16
Domain Therapeutics Enters Into Option For Licensing Agreement With Prexton Therapeutics 17
Clevexel Pharma Enters into Licensing Agreement with Domain Therapeutics 18
Domain Therapeutics Extends its Licensing Agreement with Universite de Montreal and McGill University 19
Domain Therapeutics Enters Into Licensing Agreement With Merck Serono 21
Domain Therapeutics SA – Key Competitors 22
Domain Therapeutics SA – Key Employees 23
Domain Therapeutics SA – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Strategy And Business Planning 25
Oct 18, 2016: Domain Therapeutics and Medicxi launch Mavalon Therapeutics, aimed at halting the progression of Parkinson’s disease 25
Product News 26
Feb 29, 2016: Peptimimesis: New Biotech Startup Developing Next Generation Therapeutic Peptides In Immuno -Oncology, Oncology And Immune Diseases 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
Domain Therapeutics SA, Pharmaceuticals & Healthcare, Key Facts 2
Domain Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Domain Therapeutics SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Domain Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Domain Therapeutics SA, Deals By Therapy Area, 2011 to YTD 2017 8
Domain Therapeutics SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Mavalon Therapeutics to Raise USD10 Million in Venture Financing 10
Domain Therapeutics Raises US$2.5 Million In Venture Financing 11
Domain Therapeutics Enters into Partnership with Pfizer 12
Domain Therapeutics Enters into Agreement with Xoma 13
Ono Pharma Enters Into Drug Discovery Agreement With Domain Therapeutics 14
Merck Enters into Licensing Agreement with Domain Therapeutics 15
Alkermes Enters into Licensing Agreement with Domain Therapeutics 16
Domain Therapeutics Enters Into Option For Licensing Agreement With Prexton Therapeutics 17
Clevexel Pharma Enters into Licensing Agreement with Domain Therapeutics 18
Domain Therapeutics Extends its Licensing Agreement with Universite de Montreal and McGill University 19
Domain Therapeutics Enters Into Licensing Agreement With Merck Serono 21
Domain Therapeutics SA, Key Competitors 22
Domain Therapeutics SA, Key Employees 23
Domain Therapeutics SA, Subsidiaries 24

★海外企業調査レポート[Domain Therapeutics SA-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • New Brunswick Power Corporation:企業の戦略的SWOT分析
    New Brunswick Power Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Empresas Copec S.A.:企業の戦略・SWOT・財務情報
    Empresas Copec S.A. - Strategy, SWOT and Corporate Finance Report Summary Empresas Copec S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • NII Holdings, Inc.:戦略・SWOT・企業財務分析
    NII Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary NII Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Cebu Air Inc:戦略・SWOT・企業財務分析
    Cebu Air Inc - Strategy, SWOT and Corporate Finance Report Summary Cebu Air Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Holland Colours NV (HOLCO):企業の財務・戦略的SWOT分析
    Holland Colours NV (HOLCO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • MetGen Oy:電力:M&Aディール及び事業提携情報
    Summary MetGen Oy (MetGen) is a manufacturer and distributor of enzymatic solutions. The company offers metzyme, an industrial and natural catalysts used for accelerating chemical reactions. Its enzymatic solutions find applications in various processes such as mechanical processes, lignocellulosic …
  • Rapiscan Systems, Inc.:戦略・SWOT・企業財務分析
    Rapiscan Systems, Inc. - Strategy, SWOT and Corporate Finance Report Summary Rapiscan Systems, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • First Gen Corp (FGEN):企業の財務・戦略的SWOT分析
    First Gen Corp (FGEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Mylan NV (MYL)-医療機器分野:企業M&A・提携分析
    Summary Mylan NV (Mylan) is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generics and branded medicines and consumer healthcare products. It offers pharmaceutical products in multiple forms across therapeutic categories such as respiratory and allergy, ca …
  • Guerbet SA (GBT)-医療機器分野:企業M&A・提携分析
    Summary Guerbet SA (Guerbet) is a specialty pharmaceutical company which manufactures and markets medical imaging contrast agents destined for diagnostic purposes. The company provides a wide range of contrast agents for X-ray examinations and Magnetic Resonance Imaging (MRI). Guerbet also provides …
  • Carraro Spa:戦略・SWOT・企業財務分析
    Carraro Spa - Strategy, SWOT and Corporate Finance Report Summary Carraro Spa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • eBay Inc:企業のM&A・事業提携・投資動向
    eBay Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's eBay Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital …
  • Stamps.com Inc. (STMP):企業の財務・戦略的SWOT分析
    Stamps.com Inc. (STMP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Flight Centre Travel Group Limited (FLT):企業の財務・戦略的SWOT分析
    Flight Centre Travel Group Limited (FLT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Zosano Pharma Corp (ZSAN):企業の財務・戦略的SWOT分析
    Summary Zosano Pharma Corp (Zosano Pharma), formerly ZP Holdings Inc, is a clinical stage biopharmaceutical company that develops proprietary transdermal delivery system. The company develops a transdermal microneedle patch system to deliver its drug formulations through the skin for the treatment o …
  • Telia Company AB:企業の戦略・SWOT・財務情報
    Telia Company AB - Strategy, SWOT and Corporate Finance Report Summary Telia Company AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • PQ Group Holdings Inc (PQG):企業の財務・戦略的SWOT分析
    PQ Group Holdings Inc (PQG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Kawasaki Heavy Industries Ltd (7012):企業の財務・戦略的SWOT分析
    Kawasaki Heavy Industries Ltd (7012) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Carmat SAS (ALCAR)-医療機器分野:企業M&A・提携分析
    Summary Carmat SAS (Carmat) is a medical equipment company that offers artificial organs. The company offers development of innovative artificial organs, artificial heart and other vital organs. Its artificial heart products consists of an implantable heart, and components which help connect to an e …
  • Vedanta Resources Ltd:企業の戦略的SWOT分析
    Vedanta Resources Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆